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Abstract  
Background: The introduction of the highly active 
antiretroviral therapy in the mid-1990s has significantly 
reduced morbidities and prolonged the lifespan of people 
living with HIV. However, the emergence of resistance to 
the antiretroviral drugs is becoming a major cause of 
treatment failure. While the problem of drug resistance is 
being tackled in developed countries, not much seem to 
be done in this regard in developing countries of Africa, 
Asia and Latin America. This review looked at the regional 
distribution of HIV groups and subtypes and how this has 
affected the pattern of antiretroviral resistance. 
Methods: The review was sourced from papers 
presented at international conferences on HIV/AIDS and 
rational drug use, relevant journals and Medline search 
using the keywords- Antiretroviral drugs, drug resistance, 
HIV subtypes and resistance testing.
Results: The types, groups, subtypes, sub-subtypes and 
recombinant forms of HIV-1 have been identified 
according to their geographical distributions. The 
evolution of HIV viral mutations, process (es) involved in 
development of primary and secondary antiretroviral drug 
resistance, including the role of HIV genetic 
polymorphisms, and transmitted resistance have been 
discussed. 
Conclusion: The pitfalls in the current resistance testing 
based on HIV-1 subtype B have been highlighted. The 
design of resistance testing algorithm based on HIV-1 
subtype non-B has been suggested for the developing 
world.
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Introduction
Twenty seven years after the Acquired Immunodeficiency 
Syndrome (AIDS) was first described in a cohort of 
homosexuals in the United States of America (USA), this 
deadly disease has killed well over 40 million people and 
currently affects another 33 million worldwide, over 70% 
1
of these in sub-Saharan Africa .  The human 
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immunodeficiency virus (HIV), the causative agent of 
AIDS, is classified into types, groups, subtypes and sub-
2subtypes according to its genetic diversity .  Two major 
types of HIV are currently recognized, HIV type 1 (HIV-
3
1) and HIV type 2 (HIV-2) . While HIV-2 is restricted to 
West Africa, where it represents about 3% of total HIV 
infections, and was reported to be decreasing in 
4
prevalence , HIV-1 group M is globally disseminated, 
accounting for the AIDS pandemic. Nine pure subtypes 
of HIV-1 group M (A-D, F-H, J and K) are currently 
known.    The other HIV-1 groups, O (outlier) and N 
(new or non-M, non-O) are restricted to countries of 
3central Africa, notably Cameroun and Congo . 
In 2004 a study on molecular epidemiology of HIV-1 
subtypes from 23,874 HIV-1 samples in 70 countries 
(which accounted for 89% of all people living with AIDS 
[PLHWA] worldwide) showed that HIV variants are 
heterogeneously distributed with subtype B prevalent in 
developed countries of America, Western Europe, 
Japan and Australia, while non-B subtypes predominate 
in developing countries. The non-B subtypes are 
distributed as followed-: subtype A typically found in 
Eastern Europe and countries of former Soviet Union, 
Democratic Republic of Congo (DRC) and Tanzania; 
subtype C in most countries of sub-Saharan Africa, 
Ethiopia, Zambia and India; subtype D in Libya, DRC 
2
and Tanzania; subtype F in West Africa and DRC . 
Subtypes and sub-subtypes can form additional mosaic 
forms through recombination of different strains inside 
dually-or multiply-infected individuals giving rise to 
circulating recombinant forms (CRFs). Currently over 
40 CRFs are recognized in different parts of the world 
5giving rise to 18% of infections globally .  Some of these 
CRFs have achieved epidemic relevance in certain 
geographic regions, such as CRF01_AE in Southeast 
Asian countries, CRF02_AG in West African countries, 
2
and CRF07_BC and CRF08_BC in China .  
Because these HIV-1 M subtypes and CRFs are the 
result of founder effects and localized evolution in 
different geographic locales, they are heterogeneously 
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distributed worldwide. This genetic variability of HIV-1 will 
surely impact on current efforts at virus eradication 
through development of newer antiretrovirals and vaccine 
since different subtypes display distinct biological and 
clinical properties, such as tropism, transmission 
propensities, disease progression and effectiveness 
6profile in diagnostic and monitoring assays . 
Evolution of HIV viral mutations
HIV replication is a highly dynamic process in which large 
numbers of virions are created and destroyed by the 
7immune system each day . Recent studies have 
calculated that the half-life of an HIV virion is 
approximately 30 minutes, and the production of virus can 
9 10amount to 10  to 10  virions per day. The plasma viral load 
(pVL) thus reflects the balance between the production 
8, 9
and clearance of viral particles . Most HIV-infected cells 
are short-lived T cells, which have a half-life of about 2 
days; therefore, the pool of virus-producing cells is 
maintained through the constant infection of new cells. 
Individual cells can be infected by more than 1 virion, 
which may represent different members of a pool of 
10
quasispecies . In these multiply infected cells, the 
reverse transcriptase (RT) enzyme can randomly jump 
from one ribonucleic acid (RNA) template to the other 
during viral replication, exchanging segments of genetic 
information between viral genomes. This template 
switching can facilitate the accumulation of mutations in a 
viral genome that may otherwise take a long time to 
develop. 
Genetic recombination may play an important role in the 
development of multidrug-resistant HIV strains, whereby 
a viral strain can accumulate several drug resistance 
11
mutations in a short period of time .  Mutations in the HIV 
genome are primarily generated during the initial steps of 
the HIV replication cycle. Genomic RNA carried by HIV is 
copied into deoxyribonucleic acid (DNA) early in the 
replication cycle; this process is mediated by the HIV RT 
enzyme. Spontaneous errors have been shown to occur 
during the RT process, which result in the placement of an 
incorrect nucleotide in the growing DNA strand, either as 
point mutation (e.g.,  the replacement of guanine by 
adenine, GAC to AAC) or insertion of an extra nucleotide 
(e.g., AAA-GAC-AGT to AAA-GAC-AGT-AGT). This 
happens approximately once in every 10,000 to 30,000 
12nucleotides . 
Because the HIV genome is about 10,000 bases long, an 
average of 1 error (mutation) occurs each time a viral 
genome is replicated. These aberrant nucleotides may 
result in changes in the amino acid coding of the HIV 
proteins from HIV DNA, potentially altering the structure 
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and/or function of these proteins and affecting the 
replication competence of the viral strain. Many 
examples abound; point mutation from GAC to AAC 
leads to substitution of glutamate for aspartate; 
insertion of an extra AGT leads to the production of a 
mutant serine. The first phenomenon describes the viral 
mutation as  D30N, in which the initial letter represents 
the wild-type amino acid of the protein [D: aspartate]; 
the number represents the codon or position of the 
affected amino acid within the protein [30]; and the end 
letter represents the mutant amino acid that is present 
[N:glutamate]. Thus, D30N describes the substitution of 
glutamate for aspartate at the 30 codon in HIV RT, 
representing a shift from nucleotide codon GAC 
[aspartate] to AAC [glutamate]. Since mutations in these 
proteins are the determining factor in drug susceptibility, 
the nomenclature for drug resistance mutations 
describes amino acid sequence substitutions in the 
proteins.                                                                                                                                                                                                                             
Selection of mutations by HIV-1 genome 
during antiretroviral therapy
i. Development of primary antiretroviral drug 
resistance
Factors such as viral tropism, replication kinetics and 
fitness, and host immune responses, are likely to 
influence virus transmission (both horizontal and 
vertical) and disease progression in people infected 
with different subtypes.   In uncontrolled HIV infection, 
the high HIV replication rate coupled with the RT -
induced mutation rate generates every possible 
13
mutation in the HIV genome each day . These factors 
generate a large pool of genetically related but distinct 
HIV strains called quasispecies, each of which has the 
potential to develop into the dominant strain. Most of 
these quasispecies have either deleterious mutations or 
mutations that make their growth rate inferior to that of 
other quasispecies. However, even a small proportion 
of functional mutations will generate a significant 
population of modified genomes because of the high 
overall replication rate. Strains with a mutation that 
provides a growth advantage in a particular 
environment, e.g., in the presence of antiretroviral 
(ARV) drugs will out compete the other quasispecies 
and become the dominant viral strain in the population. 
Even strains with mutations that cause impaired 
replication rate (compared with a non-mutated strain) 
can still accumulate additional mutations during 
replication, some of which can repair the strain's 
replicative defect. The character of the quasispecies 
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population is constantly shaped by both viral and host 
factors. Virus strains with replication rates that are 
severely impaired by genetic features will be less able to 
compete for target cells than strains with a higher 
replication rate, and cannot become the dominant strain 
of the viral population. Also, the immune system of the 
host may recognize and attack quasispecies that have 
specific immunologic epitopes, limiting the ability of those 
variants to complete with other quasispecies.
Antiretroviral therapy (ART) is an additional source of 
pressure on the viral population. Initial therapy with a 
potent, combination antiretroviral regimen will suppress 
the replication of most quasispecies and reduce the 
plasma viral load to a level below the limit of detection of 
sensitive viral load assays. But some variants will 
possess mutations that enable replication to occur at a 
rate determined by the inherent fitness and degree of 
resistance of the quasispecies to all drugs in the regimen. 
Studies have shown that mutations can be generated and 
viral evolution can occur even in patients undergoing 
14-16  .
highly active antiretroviral therapy (HAART) Viral 
mutations are accelerated in the presence of preexisting 
drug resistance, impotent drugs, inadequate adherence 
17- 19
and therefore inadequate drug levels  . As drug-
resistant quasispecies continue to replicate, continued 
reverse transcription events generate further mutations in 
the surviving viral population, resulting in an increased 
plasma viral load composed of quasispecies that have 
acquired sufficient resistance (and resistance mutations) 
20
to become the dominant viral strains . 
Inherent replication rate of the resistant variant also 
influences the rate of its emergence. Certain resistance 
mutations such as Y181C and K103N, which are 
associated with broad cross-resistance to the first 
generation non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), do not appear to substantially affect 
the viral replication rate; and as such, virus containing 
these mutations can appear as the dominant 
quasispecies in a matter of weeks in patients receiving 
21,22
failing nevirapine or efavirenz-containing regimens . 
On the other hand, some mutations may confer 
resistance and permit replication in the presence of the 
drug, but compromise the viral replication rate compared 
with that of wild-type virus. Strains with these types of 
mutations may take longer to emerge as a major 
quasispecies, or may acquire (through selection) 
additional compensatory mutations that help to restore 
the viral replication rate. 
High levels of resistance to some drugs, such as 
zidovudine and most protease inhibitors (PIs) may 
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require the accumulation of several mutations, which 
may involve single, double or multiple nucleotide base 
changes. And, depending on the viral replication rate, 
these mutations may take several months or years to 
occur.  Examples abound. The M184V mutation on RT 
confers high level resistance to lamivudine and 
emtricitabine, but increases susceptibility to 
23
zidovudine, stavudine and efavirenz .  Secondary 
protease (PR) mutations may confer reduced 
24, 25susceptibility to PI in vitro ; mutations D123N and 
I135T in RT of some CRF02_AG isolates have reduced 
26
susceptibility to abacavir ; mutations at positions 181I, 
188L and 190A of HIV-2 virus and HIV-1 group O 
isolates from drug-naïve Cameroonians have been 
linked to resistance to NNRTIs, the fusion inhibitors 
27-29(enfuvirtide and T-1249) and some PIs . 
Although preliminary in vitro inter-subtype differences 
in resistance to the CCR5 co-receptor antagonist 
maraviroc have not been found, reported differences in 
co-receptor tropism among subtypes may influence the 
in vivo response to that drug. For instance, subtype D 
isolates have been reported to develop CXCR4 tropism 
30
more frequently than subtype C . It is also anticipated 
that amino acid differences in proteins from non-B HIV-
1 subtypes may impair the efficacy of investigational 
drugs that are not yet even approved for clinical use. For 
example, a total of 13 amino acid differences between 
the integrase (IN) proteins of subtypes B and 
CRF02_AG have been pinpointed, which according to 
the predicted 3D model of the pre-integration complex, 
may impact on IN function. Particularly, the amino acid 
residue T125, whose variation has been implicated in 
resistance to the IN inhibitor L870, 810, differs between 
31
both subtypes . 
ii. Development of secondary antiretroviral drug 
resistance
A similar process of selection for resistance mutations 
occurs when a patient changes to a new treatment 
regimen. In this case, the rate of viral replication and 
selection of mutations is influenced by the extent to 
which the mutations selected by the previous regimen 
also confer resistance to the new drugs. If cross-
resistance exists between the previous drugs and the 
new drugs, mutation-generating replication events 
continue to occur at a rate determined by the inherent 
fitness of the viral strain and the overall effectiveness of 
the new regimen. This continued replication and 
selection is the cause of the more rapid virologic failure 
typically seen with second-line and third-line treatment 
regimens as compared with initial regimens. If the 
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mutations selected during therapy with the initial regimen 
do not confer cross-resistance to drugs in the new 
regimen, the mutant strains will be inhibited by the new 
drugs. No longer having a selective advantage, these 
variants will become minority members of the 
quasispecies population as they are out competed by 
newly selected resistant strains. The disappearance of 
mutations in the predominant population can occur in a 
matter of weeks or may take several months.
A puzzling issue in the development of drug resistance 
among different HIV-1 subtypes lies in the context of 
prophylactic ART for prevention of mother-to-child 
transmission of HIV (PMTCT). Most of the studies 
addressing this came from the use of single-dose of 
nevirapine for PMTCT in African countries. Several 
studies derived from the HIVNET 012 program in Uganda 
showed a higher occurrence of nevirapine (NVP) - related 
drug resistance, namely the mutation K103N in RT, in 
subtypes C- and D-infected women and babies compared 
32
with subtype A counterparts . Mutations K103N and 
Y181C have also been seen in subtype C-infected women 
exposed to single-dose NVP in South Africa, Zambia and 
Zimbabwe, as well as in CRF02_AG-infected women in 
32,33 34
the Ivory Coast . In 2008, Hosseinipour et al  studied 
the development of drug resistance among patients in 
Malawi who had mostly received a first-line ART 
consisting of stavudine, lamivudine, and nevirapine. 
Patients who failed were usually switched from this 
regime to one containing zidovudine, lamivudine, 
tenofovir, and lopinavir/ritonavir. Evaluation of drug 
resistance in 101 of this cohort of patients who had failed 
first-line therapy, with viral loads > 1000 copies/mL 
revealed that the most common mutation was the M184V 
followed by a number of NNRTI mutations associated with 
reduced responsiveness against nevirapine and/ or 
efavirenz. 16% of the patients had either the K65R or 
K70E mutations that are associated with stavudine failure. 
These findings confirm earlier data from Botswana that 
suggested that the K65R mutation was far likely to occur 
among patients failing a stavudine-containing regimen in 
the context of subtype C viruses than would be expected 
with viruses of subtype B origin. This finding may be of 
considerable significance in view of the fact that both 
K65R and K70E are able to confer broad cross-resistance 
against a wide array of nucleoside compounds, thereby 
potentially compromising the therapeutic usefulness of 
this family of drugs, which are the backbone of ART in 
resource poor countries.
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H I V  g e n e t i c  p o l y m o r p h i s m s  a n d  
development of antiretroviral drug 
resistance.
i. Alterations in genetic barrier to antiretroviral 
drug.
The polymorphic nature of HIV genes encoding proteins 
that are targeted by ARVs can influence the genetic 
barrier for acquiring drug-resistance mutations. The 
genetic barrier a particular HIV variant faces in reaching 
resistance is also influenced by the relative fitness 
and/or the replication capacity of the virus carrying 
particular mutations compared with its wild-type 
counterpart. Genetic differences among HIV-1 
subtypes may explain the lower occurrence of certain 
resistance mutations in particular strains. Thus, 
different drug-resistance mutations impact differentially 
on viral fitness, more in some subtypes than others. 
Mutations L210W and Q151M, both providing 
resistance to nucleoside reverse transcriptase 
inhibitors (NRTIs), can only emerge in subtype F1 after 
two nucleotide changes from a consensus baseline 
sequence, compared with other subtypes. Of note, such 
lower predicted prevalence was found in NRTI- treated 
Brazilian subjects infected with subtype F1, compared 
35
with subtypes B and C . Among European drug naïve 
subjects, additional higher genetic barrier differences 
were found for I82A in subtypes C and G and V108I in 
subtype G respectively. Conversely, a lower barrier was 
found for I82T in subtypes C and G and for V196M in 
36subtype C . D30N mutation in PR produces a lower PI 
(nelfinavir) resistance in non-B subtypes than in 
subtype B, and also impairs the replication capacity or 
37.fitness of both viruses, affecting the former more  On 
the other hand, mutations K20I and M36I in PR of 
subtype G and CRF02_AG viruses, in the absence of 
PIs, increases the replication of these isolates faster 
38than their wild-type counterparts . A drug's genetic 
barrier to viral resistance is a measure of the number of 
mutations that is required for resistance to the drug to 
develop as well as the frequency with which such 
mutations emerge. For example, it is well established 
that ritonavir-boosted PI-containing regimens have a 
higher genetic barrier to resistance than do non-
20boosted regimens, the NRTIs and NNRTIs . Also, the 
very low genetic barrier of first generation NNRTIs 
(nevirapine, efavirenz, and delavirdine) to mutations 
such as Y181C and K103N is associated with broad 
22
cross-resistance to them .  
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ii.  Developing alternative pathways to antiretroviral 
      drug resistance.
HIV variants can also display preferential selection of drug 
resistance mutations and acquisition of alternative 
pathways to drug resistance. This phenomenon is most 
prevalent among PIs, although it is seen with the other 
ARV drugs. For instance, D30N and L90M are PR 
mutations occurring in equal frequency in subtype B, but 
while D30N is selected more frequently and confer 
resistance exclusively to nelfinavir; L90M lowers 
susceptibility of this subtype to most PIs currently in 
clinical use. L90M also reduces susceptibility of non-B 
subtypes to most PIs currently in clinical use, but confers 
39
resistance to nelfinavir in these subtypes only . This 
scenario may have direct implications for nelfinavir usage 
40-42in countries where HIV-1 non-B subtypes are found . 
Other examples are; - the acquisition of a threonine (82T) 
or a methionine (I82M) mutation, at position 82 of PR of 
subtype G reduces its susceptibility to tiprinavir and 
43
indinavir respectively . CRF01_AE, on the other hand, 
appears to have a lower genetic barrier to V82F than 
subtype B, and may develop faster resistance to indinavir 
44
through this pathway .
Preferential selection of drug- resistance mutations to 
NRTIs and NNRTIs has also been described. Subtype C 
may acquire the tenofovir related mutation K65R more 
rapidly than other subtypes, perhaps influenced by 
45nucleotide polymorphisms at codons 64-66 . Different 
changes at the same amino acid residue may also be 
selected in distinct subtypes as a result of the same drug-
selective pressure. This is the case for codon 106V, which 
changes  to an alanine (106A) in subtype B, but to a 
methionine (106M) in subtype C. The 106M mutation has 
been shown to confer resistance not only to efavirenz, 
46which selects it, but to all NNRTIs .
HIV-2 exhibits more complex genetic pathways towards 
drug resistance than HIV-1, because of several 
differences in the PR and RT backbones. As a result, 
amino acid changes selected by ARVs are different and 
more difficult to interpret. For instance, PR mutation for 
47tiprinavir in HIV-2 is I82L as distinct from V82A in HIV-1 . 
Several other changes associated with drug resistance in 
HIV-2 PR, such as K7R, V62A/T and L99F are uncommon 
in HIV-1 and may even be undetected by current mutation 
48, 49interpretation rules .  
Transmitted Antiretroviral resistance 
 Drug resistance of HIV-1 to antiretroviral medications is a 
major contributor to treatment failure and, thus should be 
50prevented in its ramifications . When ART-experienced 
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persons have viral rebound, emergence of drug 
resistance should be suspected. Any resistant viruses 
that arise are archived in lymphoid tissue, and when 
present in plasma or genital secretions, are the major 
51-sources of transmission of resistant strains to others 
54. Transmitted NRTI resistance in treatment naïve 
patients may impair the potency of the backbone agents 
and, in several studies, has been associated with 
poorer virologic outcomes with first-line NNRTI-based 
23, 55 56
therapy . Furthermore, results of the GS 934 study  
22and the ACTG A5905 study  confirmed that the 
presence of detectable transmitted NNRTI resistance 
substantially decreases the likelihood of having a 
virologic response to a first-generation NNRTI-based 
regimen. Surveillance of transmitted HIV drug 
resistance in some African countries revealed that 
about 5% of Zambian adults beginning first-line therapy 
possessed at least 1 resistance-associated mutation 
33(RAM) . In HIV-2 infected, ART-experienced 
Senegalese adults, multi-class drug resistance that 
includes mutational profiles revealing high levels of 
M184V/I was commonly found , while the Q151M 
mutation that can cause broad class resistance to all 
nucleosides, and the tenofovir related mutation K65R 
was found in 9% of them. In contrast, thymidine analog-
associated mutations (TAMs) were very rare, with the 
27, 57
exception of K70R, which was found in 1 person . 
Assessment of Antiretroviral Drug 
Resistance
The prevalence of drug resistance and the role of  drug 
resistance testing as an adjunct to the management of 
patients who are initiating or changing an antiretroviral 
treatment regime has been endorsed in the recent 
50,58
update of the guidelines for resistance testing  . 
There are 2 types of assays available for measuring 
viral resistance. Genotypic assays identify specific 
nucleotide changes within the HIV-1 genome that 
correlate with drug resistance, whereas phenotypic 
tests more directly measure antiretroviral susceptibility 
in vitro by the use of a resistance test vector derived 
from viruses present in a patient plasma sample. Drug 
resistance testing can only be reliably performed if 
plasma HIV-1 RNA levels are > 500 copies/mL and 
should ideally be performed while the patient remains 
on the failing regimen so that the test results reflect the 
drug resistant viral species present under pressure of 
the treatment regimen, because some drug-resistant 
strains may not replicate as rapidly as more fit wild-type 
virus once antiretroviral treatment is modified or 
stopped. Even in some patients who have been off 
357
therapy, it is reasonable to perform drug resistance testing 
to determine the pattern of resistance of the fit viral 
population, although one must realize that without active 
drug selection pressure, resistant mutations will not be 
evident. Therefore, all previous ARV drug exposure must 
58be considered before choosing a second-line regime . 
Results of genotypic drug resistance tests are reported as 
a list of predefined drug resistance mutations, often with 
interpretations that classify individual drugs as 
“susceptible”, “possibly resistant”, or “resistant”, as 
21, 59determined by rules-based algorithms . A better 
understanding of resistance mutations and larger clinical 
trial results has allowed such algorithms to more 
accurately predict clinical response to specific drug 
regimens. However, the interpretation of resistance tests 
must take in cognizance the full drug history, including the 
current failing regimen. In cases in which resistance test 
results do not indicate selection of resistant virus at failure 
and in which the clinician believes the patient maintained 
appropriate adherence, but nonetheless failed therapy, 
there is another approach that may have value in selected 
settings.
The US Department of Health and Human Services 
(DHHS) treatment guidelines suggest that in certain 
situations, therapeutic drug monitoring may be useful in 
60patient management . However, this is currently possible 
only for the PIs and NNRTIs for which concentration-
61-63
response data exist . It can not be recommended for 
NRTIs which are probably more dependent on 
intracellular drug concentrations for their effect. This has 
therapeutic implications in developing countries where 
the NRTIs are the backbone of first-line regimen. 
Ant i ret rovi ra l  drug resistance and 
implications for clinical management of HIV 
infection in developing countries
 Current ARV drugs of all classes have been developed 
exclusively in high income countries, where a 
predominance of subtype B of HIV-1 group M is found. 
These drugs were developed through molecular 
dynamics and rational drug use, using template target 
proteins of subtype B origin. Moreover, the vast majority of 
data regarding toxicity, pharmacokinetics and the 
development of drug resistance interpretation algorithms 
and rules are being conducted in a context of subtypes B- 
infected subjects from the resource rich Western Europe 
39, 48, 49and United States of America (USA) . Presently there 
is no centre for antiretroviral drug resistance testing in 
Africa, although plans are ongoing to establish one each 
33in Zambia , South Africa and Nigeria.  Thus, the 
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effectiveness of ARV drugs and their impact on drug- 
resistance development is poorly known or understood 
for HIV-1 non- B subtypes which predominate in low 
income developing countries. Algorithms designed to 
interpret HIV genotyping resistance are ultimately 
aimed at predicting ART response and therefore 
guidance. Interpretation is based on the sequence of 
HIV genes that are targeted by ARVs such as PR, RT, 
gp41 and IN enzymes, determined from a circulating 
virus infecting an individual. Sequencing or mutation 
lists are subjected to the rules composing the algorithm, 
and a prediction of drug resistance to individual ARV 
59
drugs is provided . 
Historical models have been developed to predict that 
over the next decade, the rate of transmission of drug 
resistant virus in Africa would remain below 5% and that 
most resistant strains would result from acquired, not 
64transmitted, resistance . But these models failed to 
recognize the peculiarities of Africa in terms of diversity 
of populations, races and ethnicities.
Antiretroviral drug resistance and the future 
of HAART in sub-Saharan Africa
As antiretroviral therapy is becoming widespread in 
sub-Saharan Africa, it is expected that drug resistance, 
both primary and secondary, may become a major 
problem in future. Some studies have already shown 
that among treatment-naïve subjects initiating HAART, 
25% developed drug-resistance mutations during a 30-
month follow-up, while multi-class resistance was noted 
65 66
in about 10% .  Epidemiological studies in Europe  
67
and USA  found the prevalence of primary resistance 
to at least one drug to be 10.9% and 11.5% respectively 
in patients infected for less than 1 year, and 7.5% in 
patients infected for more than 1 year. In both studies, 
the most common resistance was to NRTIs. However, 
the emerging trend in these developed countries with 
long history of ART is that resistance is low if HAART is 
comprehensive and widely available and adherence is 
high. In sub-Saharan Africa, the current recommended 
first line regimen consisting of 2 NRTI (stavudine or 
zidovudine and lamivudine) and NNRTI (nevirapine or 
efavirenz) are not optimal enough to prevent 
development of resistance for many reasons. The high 
toxicity profiles of these drugs promote non-adherence 
and their low barrier to resistance considering reports of 
high level resistance from the use of single- dose 
nevirapine and the poor response of these patients to 
subsequent  nev i rap ine conta in ing HAART 
32
combinations . Africa will definitely not be unaffected 
by the high prevalence of NRTI resistance already 
358
68
reported in developed countries  and other parts of the 
69,70world  . Most of all, factors which are associated with 
poor adherence are prevalent in sub Saharan Africa. 
These include irregular availability and supply of ARV 
drugs, ignorance, stigmatization and poor motivations, 
poverty, malnutrition, young age and therefore illicit drug 
and/ alcohol abuse, multiple drug dosing for HIV, 
opportunistic infections(since many present at stage of 
AIDS), malaria and other co-morbidities.  
Conclusions 
The use of ART for treating HIV-infected people in 
developing countries has increased significantly in the 
past few years and has already witnessed the gains of 
reduced mortality and morbidity seen in the developed 
71
world in the mid-1990s .But this gain may be curtailed by 
the emergence of drug resistant HIV strains and 
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consequent ly  v i ro log ic  fa i lu re .  There fore  
understanding the response of different HIV variants, 
(especially HIV-1 non-B subtypes, and HIV-2 which are 
prevalent in developing countries), to ART is of 
paramount importance as the effectiveness of ARVs to 
infected patients from these areas is currently largely 
unknown. Establishment of drug resistance testing 
centres in Africa is the key to understanding drug 
resistance patterns to ARVs on this continent. This is 
fundamental to the treatment of patients who have not 
responded to or have failed a prior treatment regimen. 
Increasing international initiatives to disseminate the 
use of ART in developing countries and the design of 
more controlled and extended clinical trials and 
observational studies are needed, as these will 
ultimately lead to a better understanding of the actual 
impact of HIV variability on treatment in these areas.
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